Grifols A : Lower price for Biotest paves way for sizeable bond repurchases
The takeover offer on Biotest met lukewarm feedback from minority shareholders with only 0.2% of preference shares tendered. However, what was key for Grifols was to secure full ownership of ordinary shares, which should be achieved by April, allowing Grifols to hold all voting rights. Meanwhile, the acquisition cost is more than € 700m lower than envisaged, paving the way for bond repurchases. Most investors expect the group to redeem some of the recently issued 2028 unsecured n...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.